close 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse. Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Change languageEesti
Ülevaade
Kodu・Aktsiate loetelu・Nanobiotix
Search

Nanobiotix

Suletud

16.94 -3.2

Tugev "osta" hinnang

Hinna uuendus 7. nov 2025, 16:29 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

16.5

Max

17.28

Põhinäitajad

By Trading Economics

Sissetulek

-46M

Müük

-21M

Kasumimarginaal

221.361

Töötajad

103

EBITDA

-44M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+31.13% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

11. nov 2025

Turustatistika

By TradingEconomics

Turukapital

760M

Eelmine avamishind

20.14

Eelmine sulgemishind

16.94

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. nov 2025, 21:06 UTC

Suurimad hinnamuutused turgudel

JBS Down After Trump Calls for Probe into Meat-Packing Companies

DJ

Loe

7. nov 2025, 22:36 UTC

Tulu

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

DJ

Loe

7. nov 2025, 22:22 UTC

Tulu

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

DJ

Loe

7. nov 2025, 22:03 UTC

Tulu

Constellation Software 3Q Rev $2.95B >CSU.T

DJ

Loe

7. nov 2025, 22:03 UTC

Tulu

Constellation Software 3Q Net $210M >CSU.T

DJ

Loe

7. nov 2025, 22:03 UTC

Tulu

Constellation Software 3Q EPS $9.89 >CSU.T

DJ

Loe

7. nov 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

DJ

Loe

7. nov 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

DJ

Loe

7. nov 2025, 20:59 UTC

Tulu

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

DJ

Loe

7. nov 2025, 20:26 UTC

Market Talk

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

DJ

Loe

7. nov 2025, 20:22 UTC

Tulu

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

DJ

Loe

7. nov 2025, 20:04 UTC

Market Talk

Oil Futures Close Choppy Week With Losses -- Market Talk

DJ

Loe

7. nov 2025, 19:34 UTC

Market Talk

Gold Posts Small Gain for Week -- Market Talk

DJ

Loe

7. nov 2025, 19:31 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

DJ

Loe

7. nov 2025, 19:17 UTC

Tulu

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

DJ

Loe

7. nov 2025, 19:09 UTC

Tulu

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

DJ

Loe

7. nov 2025, 19:08 UTC

Tulu

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

DJ

Loe

7. nov 2025, 18:31 UTC

Market Talk

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

DJ

Loe

7. nov 2025, 17:27 UTC

Market Talk

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

DJ

Loe

7. nov 2025, 17:20 UTC

Market Talk

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

DJ

Loe

7. nov 2025, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

DJ

Loe

7. nov 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

DJ

Loe

7. nov 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

DJ

Loe

7. nov 2025, 17:17 UTC

Omandamised, ülevõtmised, äriostud

Satair Expects to Complete Purchase in Early 2026

DJ

Loe

7. nov 2025, 17:17 UTC

Omandamised, ülevõtmised, äriostud

Satair: Deal Includes Unical's and ecube's Seven Operational Sites and Offices, With Combined 2024 Rev of $298M and Headcount of 413

DJ

Loe

7. nov 2025, 17:15 UTC

Omandamised, ülevõtmised, äriostud

Airbus Unit Satair to Buy Unical Aviation From Platinum Equity

DJ

Loe

7. nov 2025, 17:09 UTC

Market Talk

PENN Is Falling Further Behind Competitors -- Market Talk

DJ

Loe

7. nov 2025, 16:49 UTC

Market Talk

Losing ESPN Partnership Will Hurt PENN -- Market Talk

DJ

Loe

7. nov 2025, 16:24 UTC

Market Talk

OPEC+'s Output Hike Pause Comes Amid Excess Supply, Lower Spare Capacity -- Market Talk

DJ

Loe

7. nov 2025, 16:17 UTC

Market Talk

Oil Market Faces Oversupply But "Glut" Might Be Overblown -- Market Talk

DJ

Loe

Nanobiotix Prognoos

Hinnasiht

By TipRanks

31.13% tõus

12 kuu keskmine prognoos

Keskmine 23 EUR  31.13%

Kõrge 25 EUR

Madal 21 EUR

Põhineb 3 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Põhineb 3 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Recent bullish events outweigh bearish events.

Keskpikk perspektiiv

Weak Bearish Evidence

Bearish events outweigh bullish events.

Pikk perspektiiv

Weak Bearish Evidence

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
help-icon Live chat